Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with clinical data is no easy task—especially when AC Immune’s research on misfolded proteins spans hundreds of pages of scientific detail and risk factors. If you have ever asked, "Where can I find AC Immune’s quarterly earnings report 10-Q filing?" or "How do I track AC Immune insider trading Form 4 transactions?", you know the challenge.
Stock Titan solves it. Our AI-powered summaries strip away jargon so you can understand AC Immune SEC documents with AI in minutes, not hours. From an annual report 10-K simplified to an 8-K material events explained, every document is accompanied by keyword-searchable highlights, real-time EDGAR updates, and context on why a disclosure matters. Need to monitor an unexpected clinical-trial halt? An alert appears the moment the 8-K posts. Curious about Form 4 insider transactions in real-time? Our dashboard surfaces each executive stock transaction and links it to the corresponding pipeline milestone.
The result is actionable clarity: AC Immune earnings report filing analysis that pinpoints R&D burn rate, a proxy statement executive compensation breakdown that connects pay to trial progress, and a timeline view of AC Immune executive stock transactions Form 4. Whether you’re screening for biotech catalysts, gauging partner revenue in a 10-Q, or simply need AC Immune SEC filings explained simply, everything lives here—updated the second AC Immune (ACIU) hits EDGAR.
AC Immune SA reported that it has positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial of ACI-7104.056, its wholly owned anti‑alpha‑synuclein active immunotherapy for early Parkinson’s disease. The trial is evaluating this candidate in patients with early-stage Parkinson’s.
The company disclosed that these results were first shared in a press release dated December 11, 2025, which is attached as an exhibit to this Form 6-K for more detailed information.
AC Immune SA (ACIU) submitted a Form 144 notifying the proposed sale of 45,000 common shares through Morgan Stanley Smith Barney LLC on or about 10/03/2025 with an aggregate market value of $140,850.00. The filer acquired these shares on 06/01/2012 by previously exercised stock options and paid cash for them. The filing lists recent sales by the same account under 10b5-1 plans totaling multiple transactions between 07/24/2025 and 09/29/2025, including sales of 29,400 and 5,600 shares on 09/25/2025 and 09/29/2025, respectively. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
